Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NASDAQ: IONS

Ionis Pharmaceuticals, Inc.

Healthcare | Biotechnology

No licensed closing price on file for IONS. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

EPS (TTM)$-3.46

Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-20 18:42 UTC.

What Ionis Pharmaceuticals, Inc. does

A biotechnology company specializing in RNA-targeted medicines has developed treatments for serious genetic and neurological diseases over three decades. The company currently markets seven medicines, including TRYNGOLZA for familial chylomicronemia syndrome, DAWNZERA for hereditary angioedema, and SPINRAZA for spinal muscular atrophy, with some medicines commercialized independently and others through partnerships with companies like Biogen and AstraZeneca.

Summarized from Ionis Pharmaceuticals, Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Pre-revenue, development-stage company: standard profitability ratios (P/E, EV/EBITDA, ROE) do not apply yet because there are no earnings. Watch cash, cash runway, net loss, R&D spend and share dilution instead.

Key facts

Valuation
EPS (TTM)$-3.46
Debt/equity3.60

Revenue, margins & earnings

FY2021: net loss $29M on revenue $810M$810MFY2021FY2022: net loss $270M on revenue $587M$587MFY2022FY2023: net loss $366M on revenue $788M$788MFY2023FY2024: net loss $454M on revenue $705M$705MFY2024FY2025: net loss $381M on revenue $944M$944MFY2025
  • Net income
  • Taxes & interest
  • Operating costs
  • Net loss year
Annual revenue; bands show net, operating margins · Open in Platform →

SEC Filings

SEC EDGAR ↗
Recent Insider Activity (last 90 days)
Source: SEC EDGAR · Filed 2026-10-19
  • 2026-10-19EVP, Chief Human Resources OfcRestricted Stock UnitOption exercise-2,820—
  • 2026-10-19EVP, Chief Human Resources OfcSale-1,357$59.1K
  • 2026-10-19EVP ResearchSale-53$2.3K
Sign in to see all transactions →
Recent 8-K Events (parsed from SEC filings)All events →
Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

Company news

View all →

Questions this page answers

What does Ionis Pharmaceuticals, Inc. do?

A biotechnology company specializing in RNA-targeted medicines has developed treatments for serious genetic and neurological diseases over three decades.

When did IONS last file with the SEC?

Ionis Pharmaceuticals, Inc.'s most recent SEC filing on record is a 8-K filed 2026-07-10. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-20 18:42 UTC. This page is also available as JSON at /api/data?ticker=IONS and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for IONS and 5,000+ tickers.

Create a free account — keep IONS
For your agent
GET /api/data?ticker=IONS

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt